ASH 2022 | Key highlights in CLL: clinical trial updates combination therapies novel BTKis Lindsey Roeker and Matthew Davids • 10 Dec 2022

[lankisterguy]

ASH 2022 | Key highlights in CLL: clinical trial updates & the role of combination therapies and novel BTKis

Lindsey Roeker and Matthew Davids • 10 Dec 2022

vjhemonc.com/video/m1hovnhu...

youtu.be/M1HOvNHu05w(Not working as expected?)

The treatment landscape of chronic lymphocytic leukemia (CLL) is constantly evolving, with novel Bruton’s tyrosine kinase (BTK) inhibitors transforming the field. In this discussion, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, and Lindsey Roeker, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discuss key highlights in CLL from the 2022 ASH Annual Meeting. The experts comment on the role of doublet therapies with ibrutinib and venetoclax, and discuss long-term follow-up data from several clinical trials, including CAPTIVATE (NCT02910583), ALPINE (NCT03734016), and GLOW (NCT03462719). Following this, Dr Davids and Dr Roeker highlight the growing role of triplet therapies, and further discuss the impact of novel BTK inhibitors such as zanubrutinib. This discussion took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved

-

Len

[SeymourB]

lankisterguy -

That was a concise, well presented video.

=seymour=

[spi3]

Ty for sharing! Dr Davids is my husband's Dr and he is in his O+V+A trial. hMy husband is doing fantastic. Dr Davids is really brilliant and is so excited about the newer treatments for CLL and hopes a cure will happen in our lifetime.